Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Nuno Loureiro, MIT physicist, fatally shot at home; police investigate - 2Why this Tennessee special election has the 'whole world' watching
- 3Inside the cockpit of RAF tanker during defensive mission against Iranian drones
- 44 Electric Vehicle Brands: Execution, Unwavering quality, and Development
- 5Why some African countries are prone to military takeovers
- Tyler Childers' 'Snipe Hunt' 2026 Tour: How to get tickets, presale times, prices and more
- Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- Architect Frank Gehry has died: See his most iconic buildings
- This Flashy Old-School Design Trend From Italy Still Has A Place In Modern Kitchens
- Chinese mega embassy could bring security advantages, says No 10
- How to Build a Yard That Helps Monarchs During Spring Migration
- 21 Things You Ought to Never Share with Your Childless Companion
- Journalists killed by Israeli strike in southern Lebanon
- These 45 exoplanets may be the best places to search for alien life
